Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of VIR-5500 for metastatic prostate cancer.

IDEAYA Biosciences and Servier have reported positive top line results from the Phase II/III registration trial, OptimUM-02, assessing darovasertib in combination with crizotinib for first-line ...

The FDA has sent letters to more than 2,200 sponsors and investigators regarding the failure to publish trial data from more than 3,000 studies.